Ed, here is a couple posts from the Motley Fool board which is where some of the very knowledgeable people (about Enzon) make their posts:
Subject: ANNUAL MEETING
Date: Wed, Dec 3, 1997 20:11 EST
From: PODIATRY
Message-id: <19971204011100.UAA20947@ladder02.news.aol.com>
The following is a update to the annual meeting for those who could not attend. First of all -it was very upbeat!! There is a quiet confidence being projected...These guys actually enjoyed this meeting.
1. Peg intron A -Definitely what's moving the stk for now- projections w/ Schering 1-1.50/share-5% > royalties-using conservative biotech multiples-40-60/share.....Just Peg-intron alone!! Expect good things in next 1-1/2 yrs. Schering very tight w/ info. because of competition BUT these guys know it's basically a done item-the patent runs out in 2000 so it will be quick-maybe quicker w/ FASTTRACK. We just have to wait for recognition and the
street to take notice
2. Arbitration w/ Greencross- should be good for royalties-some added bottom line in near future
3. Peg Hgb- early part of next yr- phase 2-progress has been "slower than expected"-being very prudent w/ potential mkting partners-claim to be holding for better deal-it is currently all enzons therefore i believe they know once Peg intron goes so goes Hgb an they will keep all the profit, so why rush!
3. Pro-drug transport tech- future involves antibiotics, anti-fungals,etc-sky's the limit!!
4. Protecan- enzons product-license in first half 1998 w/ IND filing, clinical trials in 1998, look for mkting partner
5. Major FDA approval for facility to manufacture products needed for clinical trials.
6. Oncaspar-40-50 mill. from sales in Canada, Germany
Again, the next big move ,imho, will be Schering and Peg-intron A-I look for news to start leaking out next yr. driving the stk. up ,more following,coverage etc. so when any announcement comes-same old story-should of bought in the single numbers!!!!!
Happy Holidays!!!!!!! 1998!!!!!!!!
Glenn
Subject: Re: ANNUAL MEETING
Date: Thu, Dec 4, 1997 08:17 EST
From: DBegley998
Message-id: <19971204131700.IAA16664@ladder01.news.aol.com>
To elaborate a bit further, Prothecan is Enzons modified version of a drug camptothesan that had toxic side effects. The former drug was very effective at killing tumors. Enzons Peged version, Prothecan, elliminates the side effects. In the model they used colon rectal tumors and found the tumors reaction was a bit delayed because of the peg, but the results were that the cancer was elliminated most of the time. In other words, this treatment was a
cure in 50+% of the cases and remission in most others. Mr Tombros said they decided to keep this drug instead of licenceing it to others. Potential major blockbuster, similar to Amgens claim to fame drugs.
Oncaspar is another sleeper, which should prove to be a big revenue stream. There are about 20 trials in different parts of the world going on right now. Mr. Tombros said 1-1 1/2 year revenues for Enzon could be anywhere from $4 to $50 million dollars, or as podiatry said up to $60 to the stock price.
Hope people get this one going over here...its one of my biggest holdings as it really looks like things are starting to happen...and they've got real business people running it now watching the cash, etc. Looks like a "crater job" that will survive and has tremendous potential....best of all some of the potential is flowering NOW and should easily keep things rolling in the future.
DAK |
